medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

**ORIGINAL RESEARCH**

**Manuscript title**

# Efficacy and Safety of Ayurveda Intervention (AYUSH 64) as add-on therapy for patients with COVID-19 infections – An open labelled, Parallel Group, Randomized controlled clinical trial

*Pankaj bhardwaj[1], Pawan Kumar Godatwar[2], Jaykaran Charan[3], Sanjeev Sharma[4], Shazia Shafi[5], Nishant Chauhan[6], Pratibha Vyas[7], Naveen Dutt[8], Naresh Midha[9], Ramniwas Jalandra[10], Meenakshi Sharma[11], Vijaya Lakshmi Nag[12], Suman Sharma[13], Sarvesh Kumar Singh[14], Praveen Sharma[15], Sanjeev Misra[16]*

[1]Additional Professor, Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences (AIIMS) Jodhpur, Rajasthan, India, [2] Professor and HOD, Department of Roga Nidana, National Institute of Ayurveda, Jaipur, Rajasthan, [3]Associate Professor, Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India, [4] Director, National Institute of Ayurveda, Jaipur, Rajasthan ,[5] Senior Resident, Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences (AIIMS) Jodhpur, Rajasthan, India, [6] Additional Professor, Pulmonary Medicine, All India Institute of Medical Sciences (AIIMS) Jodhpur, Rajasthan, India, [7] Project assistant, NIIR NCD Jodhpur, Rajasthan, India, [8] Additional Professor Department of Pulmonary Medicine , All India Institute of Medical Sciences, Jodhpur, Rajasthan, India, [9] Assistant Professor, Department of General Medicine All India Institute of Medical Sciences (AIIMS) Jodhpur, Rajasthan, India, [10] Assistant Professor, Pulmonary Medicine, All India Institute of Medical Sciences

WITHDRAWN
see manuscript DOI for details

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

(AIIMS) Jodhpur, Rajasthan, India, [11] Medical Officer, AYUSH, Jaipur, Rajasthan, [12] Professor and Head, Microbiology, All India Institute of Medical Sciences (AIIMS) Jodhpur, Rajasthan, India, [13] Associate Professor, Department of Ayurvedic Surgery, NIA, Jaipur, Rajasthan, [14] Assistant Professor, Department of Panchakarma, NIA, Jaipur, Rajasthan,[15] Professor and Head of Department , Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India, [16] Director, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.

**Correspondence**:

Dr. Jaykaran Charan

Associate Professor, Department of Pharmacology

All India Institute of Medical Sciences, Jodhpur

Email – dr.jaykaran78@gmail.com

Mobile – 9825219196

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

WITHDRAWN
see manuscript DOI for details

## Abstract

COVID-19 pandemic impacted human health and the global economy. There is a huge uncertainty about the management of this disease, many drugs including some older drugs are being tested for efficacy and safety including the medicines from the complementary and alternative system. The Central Council for Research in Ayurvedic Sciences, India's apex body for Ayurvedic research and development under the Ministry of AYUSH, has developed a poly-herbal drug called AYUSH 64 for covid 19 which is having role in the COVID-19. This study was designed with the aim of assessing the efficacy and safety of AYUSH 64 in mild covid-19 patients as add on therapy with standard treatment.

It was an open labelled, comparative, parallel group, Randomized controlled clinical trial. Total 60 stage I (mild) COVID 19 positive subjects were recruited, 30 were assigned to AYUSH 64 as an add on therapy along with the standard treatment and 30 were assigned to standard treatment as per the protocols. RT-PCR test was done as per government guidelines and protocol. Along with the RT-PCR clinical laboratory tests were also performed at screening as well as on the discharge as per the study schedule.

Absolute events of negative RT-PCR at day 5 were more in the AYUSH 64 group as compared to control group but it was not statistically significant (70% Vs 54%, p=0.28). There was no significant difference between AYUSH 64 and control group for fever and respiratory symptoms or important lab parameters. No serious adverse event was reported from any group.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

AYUSH 64 has no significant beneficial effect as compared to control group, this may be because of the less sample size or no actual effect which need to be confirmed by studies with large sample size.

**Trial Registration:** Clinical Trial Registry of India - CTRI/2020/06/026002

**Keywords:** AYUSH 64, COVID-19, Clinical Trial, RT-PCR

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

WITHDRAWN
see manuscript DOI for details

## Introduction

COVID-19 has emerged as the latest pandemic affecting millions of the people worldwide. Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. [1] World Health Organization (WHO) labelled it a Public Health Emergency of International Concern (PHEIC) on January 30, 2020, and a global pandemic on March 11, 2020. [2] Coronavirus disease is transmitted by droplets through inhalation or physical contact with the affected patient. SARS-CoV-2 is a zoonotic virus in the Coronaviridae family that can infect humans and a variety of animals. SARS-CoV-2 is believed to have been transmitted to humans by an unidentified intermediary species and then spread from human to human. [2] Looking at the morbidity and mortality associated with this disease, there is a urgent need of effective therapy for the treatment of this disease but till now no effective therapy is available.

The lack of approved effective drug therapeutic protocols for COVID-19 will make treating newly emerged COVID-19 infections around the world difficult. Not only the drug repurposing but alternative medicine system should be explored to find cure for this disease which is associated with such a high number of deaths considering overall exposed population. [3,4]

The central Council for Research in Ayurvedic sciences has developed a poly-herbal drug "Ayush - 64" whose constituents is found to be effective in various diseases having viral and parasitic origin. [5-19] The composition of AYUSH 64 includes aqueous extract of Saptaparna 100 mg (Alstonia scholaris), Katuki 100 mg (Picrorhiza kurroa), Kiratatikta 100 mg (Swertia chirata) and powder of Kuberaksha 200 mg (Caesalpinia crista) in the ratio of 1:1:1:2. As per the in-silico study based on docking, it was found that 36

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

chemical compounds of the AYUSH 64 have good potential for anti SARS COV-2 activity. [20] It was also found to be effective in Influenza like Illness (ILI) in a clinical study. [21] It was worthwhile to explore the efficacy and safety of this formulation for COVID-19, considering its good efficacy in influenza like disease. Hence this study was designed with the aim of assessing the AYUSH 64 in addition to the standard treatment in mild COVID-19 patients in addition to the standard treatment for the efficacy and safety.

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## Material and methods

### *Study design*

It was an open labelled, parallel group, prospective, Randomized clinical trial.

### *Study objectives*

The primary objective of this study was to assess the efficacy of AYUSH - 64 in the mild COVID-19 patients based on negative RT-PCR on 5$^{th}$ day of treatment. Secondary objectives were to assess the efficacy of the AYUSH 64 based on clinical and laboratory parameters and to evaluate the safety of AYUSH 64 in these patients based on hematological parameters and adverse events.

WITHDRAWN
see manuscript DOI for details

### *Subject selection*

The study was conducted in AIIMS Jodhpur on stage I (mild) COVID 19 positive patients. A total of 60 subjects were recruited. Based on the computer based randomized sequence 30 subjects were enrolled in group 1 (intervention arm) and 30 in group 2 (control arm). Subjects aged 18 to 60 years, who tested RT-PCR positive for COVID-19 and were categorized under stage I- mild (early infection), willing to take medicines orally and to provide signed informed consent were included in the study. Pregnant, Lactating women, patients with CKD (chronic kidney disease), and those not willing to participate were excluded from the study. Subjects with severe COVID-19 or acute respiratory distress syndrome or those hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation, with alanine transaminase (ALT) or aspartate transaminase (AST) more than two times the upper limit of normal, were excluded.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

***Therapeutic intervention***

Group 1 (Intervention Group): The intervention arm was given AYUSH 64, a polyherbal drug developed by Central Council of Research in Ayurveda Science (manufactured by Unijiles life sciences LTD., Nagpur, India). It was given in the dose of 2 tablets (500 mg each) thrice daily i.e. 3 gm /day orally after food along-with water for 07 days as an add-on treatment to standard care.

Group 2 (Control Group): The control group was given standard treatment as per the guideline of the Ministry of Health and Family Welfare, Government of India.

***Study procedure***

This study was started after registering trial in Clinical Trial Registry of India (CTRI) (CTRI/2020/06/026002) and getting permission from the Institutional Ethics Committee (AIIMS/IEC/2020-21/3036). The subjects were fully informed about the aims, procedures, discomforts and expected benefits of the trial by the principal investigator. COVID-19 patient diagnosed by RT-PCR who came for the treatment at the AIIMS Jodhpur were considered for inclusion. All eligible patients were randomized into the intervention and control group by computer generated randomization sequence. Allocation concealment was done centrally through telephone. Group 1 were give Ayush 64 as add on therapy along with the standard treatment for Covid patients as per the guidelines, and Group 2 were given local standard care of treatment as per the protocols. These patients were followed up for RT-PCR testing and blood parameters. RT-PCR was done on the 5th day. Repeat RT-PCR was done as per the standard protocol if needed.

Laboratory tests were performed at screening as well as on the discharge as per the study schedule which include CBC, LFT, RFT, RBS, Hs-CRP, LDH, S. Ferritin, D-

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

dimer and IL-6. Clinical parameters including symptoms and signs were assessed daily as per the standard of care. During the treatment each subject were having access to the investigators which included AYUSH practitioner also.

***Statistical analysis***

Descriptive statistics was reported in the form of frequency, percentages, mean and standard deviation. Difference in frequency of negative RT-PCR on 5th day was analyzed by Fisher's exact test and blood parameters were compared by unpaired t test. Statistics for Windows, version 23 (SPSS Inc., Chicago, IL, USA) was used for the analysis.

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## Results

All 60 subjects (30 in the intervention arm and 30 in the control arm) completed the follow up of five days. **Table 1** depicts the sociodemographic profile of the subjects enrolled in this study. There was no significant difference in any sociodemographic parameters between both groups.

On comparing both the groups for frequency of RT-PCR negative subjects on day 5$^{th}$, it was found that 21 (70%) subjects from the AYUSH 64 group and 16 (54%) subjects from control group were RT-PCR negative on 5$^{th}$ day. Though the actual events of negative RT-PCR were more in the AYUSH 64 group, but this difference was not statistically significant [p=0.28]. **(Table 2)**

WITHDRAWN
See manuscript DOI for details

There was no statistically significant difference between two groups for fever and respiratory symptoms and lab parameters. No serious adverse events reported from any group during the assessment period. **(Table 3, Table 4)**

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## Discussion

This study was designed with the aim of the assessing the efficacy and safety of the Ayush- 64 in mild cases of COVID-19 when it was given in addition to the standard treatment. It was found that conversion of RT-PCR from positive to negative was not statistically different between AYUSH 64 and control group, though absolute event of conversion was more in AYUSH 64. No difference was observed for clinical and laboratory parameters between Ayush – 64 and control group. This no significant difference between both the groups may be because of less sample size, true no difference or due to chance. A similar study using Ayush – 64 in addition with the standard treatment is now published as preprint and it shows significant beneficial effect of this intervention for COVID -19 when it was given with standard treatment in comparison to the placebo group. [22] In this study, two primary endpoints i.e mean duration of time to first day of clinical recovery was significantly less in intervention group as compared to the control group and proportion of patients with full clinical recovery was more in the intervention group as compared to the control. Quality of life score was also better in the Ayush – 64 group. There was no significant different in laboratory parameters. [22] This study has large sample size in comparison to our study though it was convenient only and exact sample size was not calculated. We have chosen the minimal sample size considering it as a new drug being explored in the disease first time and there was a plan to extend the study further if safety is established in the small sample size but it could not be done due to unavailability of the patients. In our study the primary endpoint was the conversion of RT-PCR from positive to negative. Keeping this as an endpoint has its own pros and cons. As we wanted to avoid any subjectivity and

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

bias due to open nature of the trial, we chosen RT-PCR conversion as the primary endpoint, but RT-PCR test results may be false positive as well as false negative and this may affect the overall analysis. [23] In our study there was no serious adverse event was reported while in the study by Chopra et al three serious adverse events were reported but these were from the control group and not from Ayush – 64 group. It shows that the drug has adequate safety in humans with the current dosing schedule. [22]

COVID -19 is a disease associated with high morbidity and there is need of exploration of effective interventions to prevent and treat this disease on urgent basis which can be attempted if potential therapeutic interventions from modern medicines or complementary and alternative system are explored on fast-track basis. Our study was an attempt in this direction. Looking at the positive results in the study already published as preprint and negative results in our study, the efficacy of Ayush -64 in the COVID-19 needs to be confirmed again in a large clinical trial in doble blind manner with adequate sample size. Smaller studies conducted so far can be treated as feasibility or pilot studies which can be used for better planning of large-scale clinical trials.

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

**Acknowledgments**

District Health Services of State of Rajasthan, Chief Medical Health Officer (CMHO) and his team, District administration are to be acknowledged in this present study.

**Source of Support**

This study was funded by National Institute of Ayurveda. (An autonomous body under the ministry of AYUSH), Madhav Vilas Palace, Jorawar Singh Gate, Amer Road, Jaipur-302002 (Rajasthan), India. The authors report no conflicts of interest in this work.

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## References


1. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, *et al.* The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Med Res 2020;**7,** 11 https://doi.org/10.1186/s40779-020-00240-0
2. Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B, et al. COVID-19: A promising cure for the global panic. Sci Total Environ. 2020 Jul 10; 725:138277.
3. Galindez G, Matschinske J, Rose TD, Sadegh S, Salgado-Albaraan M, Spath J, *et al.* Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. *Nat Comput Sci* **1,** 33–41 (2021). https://doi.org/10.1038/s43588-020-00007-6
4. Nugraha RV, Ridwansyah H, Ghozali M, Khairani AF, Atik N. Traditional Herbal Medicine Candidates as Complementary Treatments for COVID-19. A Review of Their Mechanisms, Pros and Cons. Evid Based Complement Alternat Med 2020 https://doi.org/10.1155/2020/2560645
5. ] Sharma KD, Kapoor ML, Vaidya Miss SP, LKS. A clinical trial of Ayush 64 (a coded antimalarial medicine) in cases of malaria. J Res Ayurveda Siddha 1980;2:309e26
6. Zhao YL, Shang JH, Pu SB, Wang HS, Wang B, et al. Effect of total alkaloids from Alstonia scholaris on airway inflammation in rats. Journal of ethnopharmacology. 2016 F;178:258-65.


WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

7. Kaushik P, Kaushik D, Sharma N, Rana A C. Alstonia scholaris: It's Phytochemistry and pharmacology. Chron Young Sci 2011; 2:71-8
8. Verma H, Patil P R, Kolhapure R M, Gopalkrishan V. Antiviral activity of the Indian medicinal plant extract, Swertia chirata against herpes simplex viruses: A study by in-vitro and molecular approach. Indian J Med Microbiol 2008; 26:322-326
9. Woo SY, Win NN, Oo MM, Ngwe H, Ito T, Abe I, et al. Viral protein R inhibitors from Swertia chirata of Myanmar. J Biosci Bioeng 2019;128:445-449.
10. Rao TS, Rao PV, Kusuma KK, Netaji B, Nisteswar K, Sharma CRR. Clinical Trial of AYUSH 64 in Sleepada. J Res Ay Sid 1982;3:9-12.
11. Pandey PN, Kishore P. Effect of AYUSH 64 and Saptaparnaghana Vati on Microfilaraemia. J Res Ay Sid 1989;12:145-50.
12. D.Bhatia. Role of AYUSH 64 in malaria epidemic. J Res Ay Sid 1997;18:71-76.
13. Zhao YL, Shang JH, Pu SB, Wang HS, Bang B, Liu L, et al. Effect of total alkaloids from Alstonia scholaris on airway inflammation in rats. J Ethnopharmacol 2016;178:258-65.
14. Nazeerullah K, Sunil K, Pal SR, Neelam D: A Pharmacognostic and pharmacological overview on *Caesalpinia bonducella*. Res J Pharma, Biol and Chem Sci. 2012, 3: 480-496.
15. Kshirsagar Sunil N. Nootropic activity of dried seed kernels of *Caesalpinia crista* Linn against scopolamine induced amnesia in mice. Int J Pharma Tech Res. 2011;3:104–109.
16. Moon K, Khadabadi SS, Deokate UA, Deore SL. *Caesalpinia bonducella* F, An

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

overview. Report and Opinion 2010;2:83–90.

17. Emmanuel N, Swaran D. Biological effects of *Caesalpinia crista* seed extracts on Helicoverpa armigera (Lepidoptera: Noctuidae) and its predator, Coccinella septumounctete (Coleoptera: Coccinellidae) J Asia-Pacific Entomol 2006;**9**:159–164.

18. Lalla JK, Ogale S, Seth S. A review on dengue and treatments. Research and reviews. J Pharmacol Toxicol Study 2014;2(4):13–23.

19. Saravanan KS, Periyanayagam K, Ismail M. Mosquito larvicidal properties of various extracts of leaves and fixed oil from the seeds of *Caesalpinia bonducella* (L) Roxb. J Commun Dis 2007;39:153-7.

20. Ram TS, Munikumar M, Raju VN, Devaraj P, Boiroiu NK, Hemalatha R, et al. In silico evaluation of the compounds of the ayurvedic drug, AYUSH 64, for the action against the SARS-CoV-2 main protease, J Ayurveda Integr Med 2021, https://doi.org/10.1016/j.jaim.2021.02.004.

21. Gundeti M, Bhurke L, Mundada P, Murudkar S, Surve A, Sharma R, et al. AYUSH 64, a polyherbal Ayurvedic formulation in Influenza like Illness: results of a pilot study. J Ayurveda Integr Med 2020 S0975-9476(20)30025-5. doi: 10.1016/j.jaim.2020.05.010

22. Chopra A, Tillu G, Chuadhary K, Reddy G, Srivastava A, Lakdawala M, et al. Coadministration of AYUSH 64 as an adjunct to Standard of Care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial. medRxiv 2021.06.12.21258345. https://doi.org/10.1101/2021.06.12.21258345

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

23. D'Cruz Roshan J, Currier Arthur W, Sampson Valerie B. Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Frontiers in Cell and Developmental Biology 2020; 8:468. https://www.frontiersin.org/article/10.3389/fcell.2020.00468 DOI=10.3389/fcell.2020.00468

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

**Table 1: sociodemographic profile of the subjects**

| | Group 1 (Ayush- 64) (n = 30, n %) | Group 2 (Control) (n = 30, n %) |
|---|---|---|
| **Gender** | | |
| Female | 1 (3.3) | 1(3.3) |
| Male | 29 (96.6 ) | 29 (96.6 ) |
| **Marital status** | | |
| Married | 22 (73.33) | 23 (76.67) |
| Unmarried | 8 (26.67) | 7 (23.33) |
| **Educational status** | | |
| Illiterate | 5 (16.67) | 2 (6.66) |
| Upto 10th | 9 (30) | 8 (26.67) |
| Upto 12th | 2 (6.67) | 7 (23.33) |
| Graduate | 12 (40) | 10 (33.33) |
| Post graduate | 2 (6.67) | 3 (10) |
| **Occupation** | | |
| Desk work | 3 (10) | 4 (13.33) |
| Field work with physical labour | 19 (63.33) | 14 (46.67) |
| Field work | 4 (13.33) | 4 (13.33) |
| House Wife | 1 (3.33) | 0 (0) |
| Student | 2 (6.67) | 3 (10) |

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

| | | |
|---|---|---|
| Others | 1 (3.33) | 5 (16.67) |
| **Socio-economic status** | | |
| Above Poverty line | 25 (83.33) | 28 (16.66) |
| Below Poverty line | 5 (16.66)) | 2 (6.06) |
| **Habitat** | | |
| Urban | 26 (86.66) | 30 (100) |
| Semi-urban | 3 (10) | 0 (0) |
| Rural | 1 (3.33) | 0 (0) |

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

**Table 2: shows the RT-PCR result of 5th day**

| **On 5th day** | Positive (n %) | Negative (n %) |
|---|---|---|
| **Group 1 (AYUSH 64)** (n = 30) | 9(30) | 21(70) |
| **Group 2 (Control)** (n = 30) | 14(46.6) | 16(53.3) |

*p*=0.28, fisher's exact test, two tailed.

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

**Table 3: Evaluation of Fever and Respiratory symptoms on 5th day**

| | Group1 (AYUSH 64) (n = 30, n %) | Group 2 (Control) (n = 30, n %) | *p* value |
|---|---|---|---|
| **Fever at evaluation** | 0(0) | 0(0) | NA |
| **History of fever** | 2(6.67) | 0(0) | 0.49 |
| **Cough** | 3(10) | 5(16.6) | 0.70 |
| **Breathlessness** | 0(0) | 0(0) | NA |
| **Sore throat** | 0(0) | 1(3.33) | 1 |
| **Sputum** | 0(0) | 0(0) | NA |
| **Nausea** | 0(0) | 0(0) | NA |
| **Diarrhoea** | 0(0) | 0(0) | NA |
| **Body ache** | 3(10) | 1(3.33) | 0.61 |
| **Abdominal pain** | 0(0) | 0(0) | NA |
| **Vomiting** | 0(0) | 0(0) | NA |
| **Nasal discharge** | 0(0) | 0(0) | NA |
| **Chest pain** | 0(0) | 0(0) | NA |
| **Anorexia** | 0(0) | 0(0) | NA |
| **Headache** | 1(3.33) | 0(0) | NA |

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

**Table 4: Evaluation of Haematological parameters on 5th day**

| | INTERVENTION | n | Mean difference | *p* value |
|---|---|---|---|---|
| **Hb** | Group 1 (AYUSH 64) | 30 | .02 | 0.72 |
| | Group 2 (Control) | 29 | .09 | |
| **TLC** | Group 1 (AYUSH 64) | 30 | -.71 | 0.77 |
| | Group 2 (Control) | 29 | -.61 | |
| **DLC N%** | Group 1 (AYUSH 64) | 30 | -.93 | 0.96 |
| | Group 2 (Control) | 29 | -.79 | |
| **DLC E%** | Group 1(AYUSH 64) | 30 | -.71 | 0.89 |
| | Group 2 (Control) | 29 | -.66 | |
| **DLC B%** | Group 1(AYUSH 64) | 30 | -.01 | 0.24 |
| | Group 2 (Control) | 29 | -.10 | |
| **DLC L%** | Group 1(AYUSH 64) | 30 | .98 | 0.89 |
| | Group 2 (Control) | 29 | 1.3 | |
| **DLC M%** | Group 1(AYUSH 64) | 30 | .70 | 0.39 |
| | Group 2 (Control) | 29 | .22 | |
| **Ab LC** | Group 1(AYUSH 64) | 30 | -.18 | 0.97 |
| | Group 2 (Control) | 29 | -.18 | |
| **D-dimer** | Group 1(AYUSH 64) | 29 | .03 | 0.39 |
| | Group 2 (Control) | 28 | .19 | |
| **RBS** | Group 1(AYUSH 64) | 29 | 5.4 | 0.45 |

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

| | | | | |
|---|---|---|---|---|
| | Group 2 (Control) | 27 | 1.4 | |
| **Urea** | Group 1(AYUSH 64) | 30 | 2.7 | 0.40 |
| | Group 2 (Control) | 30 | 1.3 | |
| **Creatinine** | Group 1(AYUSH 64) | 30 | .08 | 0.22 |
| | Group 2 (Control) | 30 | .06 | |
| **SGOT** | Group 1(AYUSH 64) | 30 | -1.6 | 0.18 |
| | Group 2 (Control) | 30 | 6.7 | |
| **SGPT** | Group 1(AYUSH 64) | 30 | 1.8 | 0.63 |
| | Group 2 (Control) | 30 | 3.7 | |
| **TP** | Group 1(AYUSH 64) | 30 | .08 | 0.65 |
| | Group 2 (Control) | 30 | .14 | |
| **ALB** | Group 1(AYUSH 64) | 30 | .004 | 0.49 |
| | Group 2 (Control) | 30 | .07 | |
| **GLB** | Group 1(AYUSH 64) | 30 | .07 | 0.91 |
| | Group 2 (Control) | 30 | .08 | |
| **Conjugated bilirubin** | Group 1(AYUSH 64) | 30 | -.03 | 0.88 |
| | Group 2 (Control) | 30 | -.03 | |
| **Unconjugated bilirubin** | Group 1(AYUSH 64) | 30 | -.09 | 0.31 |
| | Group 2 (Control) | 30 | -.03 | |
| **ALP** | Group 1(AYUSH 64) | 30 | -4.3 | 0.16 |
| | Group 2 (Control) | 30 | 7.7 | |
| **LDH** | Group 1(AYUSH 64) | 30 | 4.4 | 0.78 |
| | Group 2 (Control) | 29 | 9.0 | |

WITHDRAWN
see manuscript DOI for details

medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261836; this version posted August 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

| | | | | |
|---|---|---|---|---|
| **Ferritin** | Group 1(AYUSH 64) | 30 | -.25 | 0.88 |
| | Group 2 (Control) | 30 | -3.1 | |
| **Hs -CRP** | Group 1(AYUSH 64) | 30 | .70 | 0.44 |
| | Group 2 (Control) | 30 | 2.9 | |
| **IL – 6** | Group 1(AYUSH 64) | 30 | -.23 | 0.61 |
| | Group 2 (Control) | 29 | -15.2 | |

WITHDRAWN
see manuscript DOI for details